Aezs estoque zacks

04/12/2018 · The Zacks Consensus Estimate for AEZS's full-year earnings has moved 780% higher within the past quarter. This is a sign of improving analyst sentiment and a positive earnings outlook trend. Based on the most recent data, AEZS has returned 63.98% so far this year. 01/08/2019 · The market expects Aeterna Zentaris (AEZS) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2019. This widely-known consensus outlook is important in assessing the company's earnings …

07/12/2018 · AEZS is currently sporting a Zacks Rank of #1 (Strong Buy). Valuation is also important, so investors should note that AEZS has a Forward P/E ratio of 8.39 right now. This represents a discount compared to its industry's average Forward P/E of 23.14. What's in the Cards for Aeterna (AEZS) This Earnings Season? Feb 27, 2019. The Zacks Analyst Blog Highlights: Celgene, Charles River Laboratories International, Catalent and Aeterna Zentaris. Feb 26, 2019. 4 Drug Stocks to Buy Despite Price Hearing Woes. Feb 14, 2019. The Zacks Analyst Blog Highlights: BioDelivery, Cytokinetics, Celldex, Aduro Find the latest Aeterna Zentaris Inc. (AEZS) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors. 24/12/2019 · Shares of AEterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ) have been assigned an average broker rating score of 1.00 (Strong Buy) from the one analysts that cover the stock, Zacks Investment Research reports. Zacks has also assigned AEterna Zentaris an industry rank of 64 out of 255 based on the ratings given to related companies.

24/12/2019 · Shares of AEterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ) have been assigned an average broker rating score of 1.00 (Strong Buy) from the one analysts that cover the stock, Zacks Investment Research reports. Zacks has also assigned AEterna Zentaris an industry rank of 64 out of 255 based on the ratings given to related companies.

AEZS: AEterna Zentaris Inc. - Earnings Announcements. Stay up to date with lastest Earnings Announcements for AEterna Zentaris Inc. from Zacks Investment Research Aeterna Zentaris (AEZS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. AEZS. earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank. Should I buy Aeterna Zentaris Inc. (AEZS)? Use the Zacks Rank and Style Scores to find out is AEZS is right for your portfolio. Investors might want to bet on Aeterna Zentaris (AEZS), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. 07/12/2018 · AEZS is currently sporting a Zacks Rank of #1 (Strong Buy). Valuation is also important, so investors should note that AEZS has a Forward P/E ratio of 8.39 right now. This represents a discount compared to its industry's average Forward P/E of 23.14.

AEZS Real Time Stock Quote - Get Aeterna Zentaris Inc. Common Stock (AEZS) last sale data in real-time at NASDAQ.com.

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing pharmaceutical therapies for treating oncology and endocrinology. 29/01/2019 · The Zacks Consensus Estimate for AEZS's full-year earnings has moved 708.11% higher within the past quarter. This is a sign of improving analyst sentiment and a positive earnings outlook trend. Based on the most recent data, AEZS has returned 30.95% so far this year. 13/08/2019 · Aeterna Zentaris (AEZS) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.14 per share. This compares to loss of $0.16 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings AEterna Zentaris Inc. (NASDAQ:AEZS) announced its quarterly earnings results on Thursday, November, 7th. The biopharmaceutical company reported ($0.02) EPS for the quarter, beating the Zacks' consensus estimate of ($0.17) by $0.15. 07/01/2019 · Looking more specifically, AEZS belongs to the Medical - Biomedical and Genetics industry, which includes 345 individual stocks and currently sits at #58 in the Zacks Industry Rank. This group has gained an average of 6.19% so far this year, so AEZS is performing better in this area.

14/05/2018 · Chicago, IL - May 14, 2018 - Stocks in this week's article include: Weight Watchers International, Inc. WTW, Aeterna Zentaris Inc. AEZS, TransUnion TRU, Six Flags Entertainment Corporation SIX and Johnson Outdoors Inc. JOUT. Screen of the Week of Zacks Investment Research: Top 5 Profitable Stocks

29/10/2019 · AEterna Zentaris Inc. company facts, information and stock details by MarketWatch. View aezs business summary and other industry information. Investors in Aeterna Zentaris Inc. AEZS need to pay close attention to the stock based on moves in the options market lately. That is because the August 18 th, 2017 $7.50 Call had some of the highest implied volatility of all equity options today. Aeterna Zentaris (AEZS) Reports Q1 Loss, Misses Revenue Estimates Zacks Equity Research - Zacks Investment Research - Tue May 7, 6:25PM CDT Zacks Equity Research - ZACKS - Tue May 7, 6:25PM CDT Aeterna Zentaris (AEZS) delivered earnings and revenue surprises of -450.00% and -99.12%, respectively, for the quarter ended March 2019. 14/05/2018 · Zacks Rank equal to #1: Only Zacks Rank #1 (Strong Buy) stocks are allowed. With the Zacks Rank proving itself to be one of the best rating systems out there, this is a great way to start things off. 12-Month Trailing Sales and Net Income Growth Higher than X Industry: Stocks that possess higher sales and net income growth in the last 12 months showcase better financial performance.

View the latest AEZS stock quote and chart on MSN Money. Dive deeper with interactive charts and top stories of Aeterna Zentaris Inc.

Stock quote and company snapshot for AETERNA ZENTARIS INC (AEZS), including profile, stock chart, recent news and events, analyst opinions, and research reports. AEZS Real Time Stock Quote - Get Aeterna Zentaris Inc. Common Stock (AEZS) last sale data in real-time at NASDAQ.com. Researching AEterna Zentaris (TSE:AEZ) stock? View AEZ's stock price, price target, earnings, forecast, insider trades, and news at MarketBeat. AEterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ) has been assigned an average broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the company, Zacks Investment Research reports. Zacks has also assigned AEterna Zentaris an industry rank of 66 out of 255 based on the ratings given to its competitors. A number […] Shares of AEterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ) have earned an average broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the company, Zacks Investment Research reports. One analyst has rated the stock with a strong buy rating. Brokerages have set a 12-month consensus target price of $4.50 for the […] What Makes Aeterna Zentaris (AEZS) a New Buy Stock Zacks Equity Research - Zacks Investment Research - Tue Oct 8, 8:00AM CDT Zacks Equity Research - ZACKS - Tue Oct 8, 8:00AM CDT Aeterna Zentaris (AEZS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.

Stock quote for Aeterna Zentaris Inc. Common Stock Common Stock (AEZS) with real-time last sale and extended hours stock prices, company news, charts, and research at Nasdaq. Get breaking news and analysis on Aeterna Zentaris Inc. (AEZS) stock, price quote and chart, trading and investing tools. Æterna Zentaris Inc. (TSX: AEZ, NASDAQ: AEZS) is a late-stage oncology drug development company currently investigating potential treatments for various cancers including colorectal, multiple myeloma, endometrial, ovarian, prostate and bladder cancer.The Company's innovative approach of "personalized medicine" means tailoring treatments to a patient's specific condition and to unmet medical 12/01/2020 · Find the latest Aeterna Zentaris Inc. (AEZS) stock quote, history, news and other vital information to help you with your stock trading and investing. Options Traders Expect Huge Moves In Aeterna Zentaris (AEZS) Stock By Zacks Investment Research - Jun 30, 2019. Investors in Aeterna Zentaris Inc. (TSX:AEZS) need to pay close attention to the stock based on moves in the options market lately. That is because the Aug 16, 2019 $7.50 Call AEterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ) has been assigned a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that cover the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy recommendation. Zacks Investment Research cut shares of AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) from a buy rating to a hold rating in a research note issued to investors on Monday morning, Zacks.com reports. According to Zacks, “AEterna Zentaris Inc. is a biopharmaceutical company focused on endocrine therapy and oncology. Its lead endocrinology program is